Abstract

The buccal route of administration has a number of advantages including bypassing the gastrointestinal tract and the hepatic first pass effect. The successful delivery of drugs across the oral mucosa represents a continuing challenge, as well as a great Opportunity. The Levosalbutamol sulphate is a β adreno-receptor agonist used for the maintenance, treatment of chronic asthma attacks and to relieve Chronic obstructive pulmonary diseases (COPD) Because of poor bioavailability of Levosalbutamol sulphate by oral route, there is a need to increase its bioavailability by formulating it into buccal dosage forms. The buccal tablets of Levosalbutamol sulphate were prepared by direct compression method. The tablets were evaluated based on their physical characteristics like, weight variation, thickness, hardness; their mechanical properties are found within the prescribed limits. Swelling index of all the formulations were between ranges of 18.56±0.55 to 89.31±0.07. Surface pH, friability, like in vitro residence time and their evaluations like, drug content uniformity are found within the ranges, the ranges of (F1- F6) and in vitro study shows 50.09% to 78.78% among these the formulation (F4) shown highest drug release of 78.78±2.00% at the end of 8 hours. The FTIR study reveals that there was no interaction between API and excipients. It was observed that all preformulation and formulation parameters were acceptable with reasonable limits of standards required for buccal tablets which may enhance the absorption of drug with increased residence time in buccal cavity avoiding first pass metabolism may also leads to increased bioavailability.